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Abstract: Accumulating evidence in mice models of accelerated senescence indicates a rescuing
role of ascorbic acid in premature aging. Supplementation of ascorbic acid appeared to halt cell
growth, oxidative stress, telomere attrition, disorganization of chromatin, and excessive secretion
of inflammatory factors, and extend lifespan. Interestingly, ascorbic acid (AA) was also found
to positively modulate inflamm-aging and immunosenescence, two hallmarks of biological aging.
Moreover, ascorbic acid has been shown to epigenetically regulate genome integrity and stability,
indicating a key role of targeted nutrition in healthy aging. Growing in vivo evidence supports
the role of ascorbic acid in ameliorating factors linked to Alzheimer’s disease (AD) pathogenesis,
although evidence in humans yielded equivocal results. The neuroprotective role of ascorbic acid not
only relies on the general free radical trapping, but also on the suppression of pro-inflammatory genes,
mitigating neuroinflammation, on the chelation of iron, copper, and zinc, and on the suppression of
amyloid-beta peptide (Aβ) fibrillogenesis. Epidemiological evidence linking diet, one of the most
important modifiable lifestyle factors, and risk of Alzheimer's disease is rapidly increasing. Thus,
dietary interventions, as a way to epigenetically modulate the human genome, may play a role in
the prevention of AD. The present review is aimed at providing an up to date overview of the main
biological mechanisms that are associated with ascorbic acid supplementation/bioavailability in the
process of aging and Alzheimer’s disease. In addition, we will address new fields of research and
future directions.
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1. Ascorbic Acid and Its Relevance to the Aging Process
Due to the aging population and the increased life-expectancy [1] in developed and developing
countries, a growing area of interest concerns the understanding of the mechanisms that regulate
aging and that differentiate successful aging from pathological aging. Prolonged exposure to antigens
throughout life produces a progressive modification of the individual homeostasis [2].
The free radical theory of aging allows an explanation of the molecular mechanisms underlying
the aging process, at least partially, and the pathogenesis of age-related diseases, such as
atherosclerosis, cardiovascular diseases, dementia, diabetes, and osteoporosis [3,4]. From a biological
perspective, the process of aging is characterized by immunosenescence: this may be defined as
the reduced ability to respond to foreign antigens and to tolerate self-antigens, leading to increased
susceptibility to infections, cancer, and autoimmune diseases [5]. The most accredited molecular
mechanisms for immunosenescence include redox-mediated and mitochondria-dependent oxidative
pathways. High levels of free radicals and peroxidation products of lipid membranes, such as
malondialdehyde (MDA), are able to modulate the activation of nuclear transcription factors,
associated with cell aging and longevity, such as tumor protein p53, transcriptional protein AP-1
and nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB). In addition, these same
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mechanisms are responsible for altered T cell expression and the altered phenotype of immunological
subpopulations [6].
Oxidative stress is increasingly considered to be the major epigenetic factor for aging and also
plays an important role in inducing the low-grade inflammation, as the two processes are strictly
intertwined. This pro-inflammatory phenotype, defined ‘inflamm-aging’, is characterized by an
increased expression of genes related to inflammation and to the immune response. Indeed, it is
known that the increased serum levels of C reactive protein (CRP) and pro-inflammatory cytokines,
such as interleukin-6 (IL-6) and tumor necrosis factor alpha (TNF-α) induce the activation of NF-KB
mediated superoxide production in mitochondria, promoting the release of oxygen reactive species
(ROS) [2,6].
Inflamm-aging is also associated with decreased nitric oxide (NO) bioavailability in the endothelial
layer, which induces endothelial dysfunction. Inflamm-aging may be considered a biological
background for both the aging process and the pathophysiological process of frailty in humans [7].
The endogenous antioxidant enzymatic defense system superoxide dismutase (SOD), catalase
and glutathione peroxidase (GSH) counteracts oxidative exogenous agents from diet and may undergo
substantial decrease related to the aging process [8]. Accumulating evidence indicates that nutrition is
a key relevant factor for inflamm-aging and an important modulator of the aging process as well [9–11].
Ascorbic acid (AA) is a powerful first-line antioxidant that mediates several beneficial effects on
redox oxidative pathways and mitochondrial pathways on the immune system, on inflamm-aging,
on endothelial integrity, and on lipoprotein metabolism [12,13]. AA, a lactone with six carbon atoms,
is synthesized from glucose in the liver of many species of mammals. Humans have evolutionarily
lost the gulonolactone oxidase enzyme, essential for the synthesis of 2-keto-L-gulonolactone, its direct
precursor. As a result, people absorb AA exclusively from the diet. AA enters the cells through the
sodium-dependent vitamin C transporters SVCT1 and SVCT2, a process favored by the electrochemical
sodium gradient: due to its high capacity and low affinity, SVCT1 assures the intestinal and renal
absorption and reabsorption [14].
All of the physiological and biochemical actions of AA are due to its ability to donate electrons
(as a reducing agent). AA undergoes two consecutive and reversible oxidations: from the first electron
loss, it generates an intermediate product, the ascorbate free radical (AFR), which is converted into
dehydroascorbate (DHA) after the loss of the second electron. At physiological concentrations, AA is
a powerful antioxidant and scavenger of free radicals in plasma and different tissues, including the
central nervous system (CNS) [15,16].
AA is also implicated in the endothelial integrity associated with NO bioavailability [17]. The
molecular mechanisms that induce endothelial dysfunction affect the enzyme NO synthase (eNOS)
by impairing Gi- dependent signaling, decreasing mRNA stability for eNOS, and blocking eNOS
translocation from the plasma membrane to the Golgi membranes. The reduced bioavailability of its
substrate (L-arginine) or its co-factor (tetrahydrobiopterin BH4) was also observed [18]. Low levels of
BH4 compromise eNOS function by promoting the transfer of electrons to oxygen molecules instead of
L-arginine: in turn, eNOS produces a superoxide anion instead of generating NO [19].
2. Ascorbic Acid, Epigenetic Modulation and Nutrigenomics
In the last decades, the understanding of AA properties has undergone a major revolution, ranging
from a simple antioxidant to a micronutrient, capable of epigenetic regulation [20,21].
Recent advances in epigenetics have identified a series of di-oxygenases Fe2+ and 2 oxoglutarate
(2OG-dependent) enzymes that catalyze the epigenetic modifications of DNA and histones. Some
of these enzymes require ascorbate to maintain their catalytic activity. Therefore, the availability of
ascorbate might affect the epigenome, with a potential impact on health and age-related diseases.
Methylation in the C5 position of cytosine (5-methylcytosine, 5mC) is the most important and
well-studied epigenetic mark of mammalian DNA, which plays an essential role in the transcriptional
and in the maintenance of genome stability.
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DNA methyltransferase (DNMTs) is responsible for the transfer of a methyl group from the
universal methyl donor, S-adenosyl-L-methionine (SAM), to the 5-position of cytosine residues in
DNA. The presence of an unusual nucleotide, 5-hydroxymethylcytosine (5hmC) in mammalian DNA
has been reported. Although 5hmC represents less than 1% of total nucleotides, high levels have
been observed in the cerebellar Purkinje cells and in the granule neurons, suggesting a potential role
for neuronal functions in epigenetic regulation. This nucleotide (5hmC) is formed by the activity of
a group of enzymes, ten-eleven translocation methylcytosine dioxygenas (TET: TET1, TET2, TET3),
that catalyze the ten-eleven translocation and oxidize 5mC to generate 5hmC. TET enzymes were
shown to further oxidize 5hmC into 5-formylcytosine (5fC) and 5-carboxylcytosine (5caC). Ascorbic
acid is known to increase 5hmC production in a TET-dependent way, probably by reactivating the
catalytic site of TET enzyme, reducing Fe3+ to Fe2+. Namely, AA induced a significant demethylation
of 5-methylcytosine (5mC) to 5-hydroxymethyl cytosine (5hmC) [22,23].
Variation in ascorbate bioavailability can influence the demethylation of DNA and histones: in
addition, ascorbate deficiency can present at different stages of aging and could be involved in the
development of different age-related diseases. In particular, if additional ascorbate is not provided by
supplementation or improved uptake, there would be progressive AA decline in the brain, which might
be associated with neurodegeneration. So far, there is inconsistent data on epigenetic modifications in
the human brain. Further studies could unravel the potential impact of age-related ascorbate decline
on the epigenome and on neurodegeneration.
So far, AA seems to increasingly have beneficial effects on the aging processes and on
the prevention of age-related diseases as atherosclerosis, cardiovascular diseases, cancer, and
neurodegenerative diseases.
Nutrigenomics is a young area of research, but meaningful studies indicated a role for AA on gene
expression. A previous study found that, although no diet-gene interactions were observed, genetic
variation of SVCT1 can influence serum ascorbic acid concentrations. Moreover, both AA transporter
genotypes modify the strength of the correlation between dietary AA and serum levels [24].
Recently, genetic variations of haptoglobin, polymorphisms in the transporters of AA, and deleted
polymorphisms of glutathione-S-transferase have provided genetic information regarding possible
relative AA levels [25–27].
Intriguingly, AA functions at the interface of different molecular pathways associated with aging,
as illustrated by Figure 1.
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Figure 1. AA is at the crossroads of biological aging, intercepting immunosenescence, inflamm-aging,
and oxidative stress (free radical theory of aging), with a potential role in the onset of age-related
diseases and frailty trajectories.
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3. Ascorbic Acid and the Aging Process: In Vitro Models
Several lines of research have increasingly accredited the role of AA in the aging process. The
in vitro and in vivo evidence is reported herein and illustrated in Table 1.
Table 1. In vitro and in vivo evidence for a role of AA in the aging process.
Species Model Design and Methods Conclusion References
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A mouse model of senescence showed that AA promotes proliferation of bone marrow
mesenchymal cells derived from aging mice. The senescence-accelerated mouse prone 6 (SAMP6) mice
and senescence-accelerated mouse resistant 1 (SAMR1) mice were used as the test group and the control
group, respectively. Bone marrow mesenchymal stem cells (BMMSCs) derived from SAMP6 mice were
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treated with increasing concentrations of AA [44]. The treatment significantly improved the BMMSCs
proliferation in a dose-dependent manner by increasing telomerase activity and TERT expression.
The AA concentration of 100 µg/mL induced the strongest effect in promoting the proliferation of
BMMSCs in SAMP6 mice, while at a concentration of 1.000 mg/mL, AA suppressed the cell growth.
AA can promote the proliferation of BMMSCs from aging mice, possibly by increasing the cellular
telomerase activity.
Interestingly, it is known that bone marrow (BM) plays a key role in immunological memory and
surveillance, through inflamm-aging. Overexpression of IL-15 and IL-6 was stimulated by IFN-y and
correlated with ROS. The plasma-cell survival factor a proliferation- inducing ligand (APRIL) was also
reduced. AA was effective in counteracting inflammatory- and oxidative stress-related changes in the
aging bone marrow, improving immunological memory in old age. This study is of key relevance in
assessing the protective role for AA in immunosenescence [35].
The positive effects of AA on premature cellular events was confirmed by treatment with
AA on Werner’s syndrome protein (WRN-deficient) human mesenchymal stem cells (MSCs) [33].
In this model, the analysis of mRNA levels showed that AA altered gene expression was involved
in chromatin condensation, the regulation of the cell cycle, and DNA replication and repair. AA
promoted heterochromatin remodeling to a younger state (as demonstrated from the upregulation
of heterochromatin Protein 1 (HP1α) markers and histone H3K9me3 by Western blotting). AA
slowed down cellular senescence in mesenchymal WRN-deficient cells (as demonstrated by the
SA-β-gal staining) restoring mesenchymal stem cells’ vitality and proliferative potential. AA repressed
telomere shortening, decreased the production of pro-inflammatory cytokines, such as IL-6 and IL-8,
downregulated the expression of markers of aging, such as cyclin-dependent kinase inhibitor 2A,
multiple tumor suppressor 1 p16Ink4a and zinc finger transcriptional GATA4, and repressed the SASP
(elevated senescence-associated secretory phenotype). AA was effective at alleviating aging defects by
reducing cell cycle regulation, telomere attrition, ROS burst, and nuclear laminin disorganization.
AA was also reported to stimulate/inhibit the differentiation of mesoderm-derived embryonic
stem cells (ES) through the involvement of p38 mitogen activated protein kinase/cAMP response
element binding (CREB) nuclear transcription factor activation (p38 MAPK/CREB pathway) and
increased expression of the SVCT2 transporter. More precisely, AA was found to promote ES
differentiation by regulating chromatin domain overlapping. These in vitro models have important
implications for the aging process. The effect of AA in the context of body weight could be at
least partially related to stem cell differentiation towards myogeneis and osteogenesis, inhibiting
adipogenesis. Since aging is associated with sarcopenia and defects in body weight, the current
observations suggest that AA-mediated stem cell effects could play a role in the aging process [36,37].
Furthermore, the same results were replicated in human bone marrow mesenchymal stromal cells
(hBM-MSCs) undergoing replicative senescence to investigate the relationship between ROS levels and
stem cell potential differentiation after AA treatment. Interestingly, AA supplementation eliminated
ROS excess and restored the endogenous antioxidant enzymatic activity (catalase, SOD) by influencing
phosphorylated fox head box O protein 1 (p-FOXO) and p53. Moreover, differentiation into adipocytes
and osteocytes was significantly increased [38].
Thus, AA seems to be implicated in the regulation and differentiation of stem cells. Current
knowledge on MSC cell surface biomarkers and molecular mechanisms of MSC differentiation
emphasizes the role of Wnt/β-catenin signaling, the Notch signaling pathway, bone morphogenesis
proteins, various growth factors, and oncogene and immunosuppressive activities of MSCs. Therefore,
further investigations are needed to establish a role for AA in such targeting regulation of cell
differentiation, which may have important clinical implications for the prevention of age-related
disease [45].
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Ascorbic Acid and the Aging Process: In Vivo Evidence
Murine models of Werner’s syndrome (WS) (Wrn ∆hel/∆hel mutants) exhibit many phenotypic
characteristics similar to accelerated human aging. The supplementation with AA for nine months was
found to reduce oxidative stress in hepatocytes and cardiomyocytes, and decrease hypertriglyceridemia
and hyperglycemia. A significant improvement of the metabolic profile, including insulin resistance
and the body fat in Wrn∆hel/∆hel mutant mice was also observed.
Similarly, other Werner syndrome-like in vivo models have confirmed that AA supplementation
rescued the shorter lifespan, reversing age-related abnormalities in adipose tissue, the liver, and
genome integrity. In the metabolic profile, inflammatory status was improved and, at a molecular
level, the normalization of the phosphorylation of AKT kinase, transcriptional levels of NF-kappa B,
protein kinase delta (PKC delta), peroxisome proliferator-activated receptor alpha (PPAR-alpha) and
hypoxia-inducible factor-1 alpha (HIF1-alpha), were observed [45].
A further study of Wrn∆hel/∆hel mutant mouse models showed that the pro-oxidant and
inflammatory state produced a premature defenestration of sinusoidal endothelium in liver tissue with
consequent hepatic dysfunction and impaired hepatic lipoprotein metabolism. Long-term treatment
with AA restored physiological levels of GSH and the fenestrated sinusoidal endothelium by quenching
oxidative stress. It is noteworthy that in healthy mice, the beneficial effects of AA on health and lifespan
were not significant and the supplementation significantly reduced the oxidative damage only in
Wrn∆hel/∆hel mouse liver [30,34].
AA had a positive impact on the cardiometabolic and inflammatory profiles of mice lacking
the functional Werner syndrome protein helicase. AA reversed changes in the expression levels of
plasminogen activator-1 (PAI-1) and improved, at a transcriptional level, fatty acid degradation. In
addition, AA increased glutathione metabolism and reversed the oxidative stress. This study suggested
that AA could be a potential cardiometabolic biomarker in patients with WS [39].
Caenorhabdilis elegans worm models, with a non-functional wrn-1 DNA helicase ortholog, exhibited
a shorter lifespan. The supplementation with AA increased lifespan in the mutant strain, compared
with the wild-type strain possibly by altering the expression of genes regulating the metabolism of
lipids, ketones, organic acids, and carboxylic acids. AA modified the expression of genes involved in
locomotion and development of the anatomical structure. Conversely, in the wild-type worms, AA
only influenced the biological process of proteolysis [32].
Knockout (Gulo−/−) mice represent an interesting in vivo model that mimics human physiology,
lacking the gulonolactone oxidase (Gulo) gene. Accumulating evidence from this in vivo model
yielded additional information on the role of ascorbate in aging. Knockout (Gulo−/−) mice developed
high oxidative stress, sensorimotor deficits, and behavior abnormalities. The lifespan of Gulo−/−
mice appeared to inversely correlate with the phosphorylation levels of IRE1α and IF2α, in response
to endoplasmic reticulum stress. In this model, AA supplementation reduced phosphorylated IRE1α,
implicating its protective effect on endoplasmic reticulum stress and extended lifespan. In addition, in
the same in vivo model, AA supplementation was shown to improve T cell-mediated acute response
after liver injury, suggesting a modulation of the immune system [31].
Uchio et al. demonstrated the influence of long-term high-dose AA intake on the number and
function of immune cells in SMP30KO mice. The total counts of leucocytes, lymphocytes, granulocytes,
and monocytes in the peripheral blood, as well as the number of splenocytes and thymocytes, were all
significantly higher in the treated group. In addition, the number of naive T cells in peripheral blood
lymphocytes, the number of memory T-cell populations in splenocytes, and the number of clusters of
differentiated CD4+ and CD8+ T cells in thymocytes were all remarkably elevated. High dietary AA
intake was associated with the improvement of age-related thymic atrophy. The study indicated a role
for AA in immunosenescence by targeting CD4+ and CD8+ cells. Further, AA was found to modulate
immune cell surveillance in SMP30 knockout mice [40].
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In line with these data, Sato and colleagues suggested that AA plays an important role in
preventing protein oxidation in the liver of SM30/gluconolactonase knockout mice, with potential
implications in overall health and aging [41].
4. Ascorbic Acid and the Aging Process: Oxidative Stress and Antioxidant Defense
Oxidative stress is considered noxious for lifespan and AA, and, as a first line antioxidant, has
been thought to potentially increase longevity. These notions have recently been challenged by
findings in model organisms that show beneficial effects on lifespan of increased ROS generation
produced by mutations or pro-oxidant treatments [46,47]. Such a relationship would arise from a
combination of beneficial effects from a moderate increase in ROS levels and their dose-dependent
toxicity. Intriguingly, the small elevation of ROS levels that increase lifespan seems not to be stressful,
nor do they induce an increased resistance to oxidative stress. In particular, in a Caenorhabdilis elegans
model, [48] AA displayed an inverted U-shaped dose–response relationship between ROS levels
and lifespan; both high and low levels of ROS were detrimental for longevity. This evidence further
complicated the role of AA in aging. The fact that both antioxidant and pro-oxidant treatments reveal
such a different behavior suggests that temporal administration of AA is of key relevance to obtain
beneficial effects. Moreover, ROS levels still need to be optimized for lifespan in different cells, and the
net balance between antioxidant and oxidant defense and their concentrations plays a relevant role in
the aging process.
From a clinical perspective, AA functions at a true interface between aging, life span and
age-related diseases. It is able to modulate telomeres activity, bioenergetics, DNA repair and oxidative
stress, indicating a nutrigenomic role in the process of aging as well [49].
During aging, the antioxidant capacity of AA is finely regulated by the redox balance of
DHA/ascorbate and the ability of the endogenous antioxidant enzymatic defense system (glutathione
and nicotinamide adenine dinucleotide phosphate; NADPH) to recycle DHA back to AA. An increased
ratio of DHA/AA becomes an indicator of a pro-oxidative ability of AA to mediate biological processes
and may play a role in age-related diseases, intercepting different aging trajectories.
Similarly, cellular antioxidant enzymatic capacity declines during the aging process and oxidation
of glutathione and NADPH may also explain different results in studies targeting aging and disease
prevention. Recently, it has been shown that elderly people with lower peripheral antioxidant
parameters, including AA and a decreased antioxidant capacity, are more prone to clinical vulnerability,
disability, frailty and higher mortality over a 5-year follow up [50].
Conversely, two studies in healthy elderly subjects showed that daily intake of star fruit
juice (Averrhoa Carambola, a fruit with high content of AA) acted as a scavenger of free
radicals, and maintained low levels of lipoperoxidative stress (MDA), restoring GSH levels. The
associated AA antioxidant capacity also mediated anti-inflammatory effects by the reduction of
pro-inflammatory cytokine secretion, especially TNF-alpha and interleukin-23 (IL-23) excluding
interleukin-2 (IL-2) [51,52].
Kim et al. investigated the effects of high-dose AA supplementation (1250 mg daily) in humans.
After eight weeks, the analysis of serum lipoproteins showed a reduction of advanced glycation end
products (AGEs). The anti-glycoxidative effect was significantly higher, especially in non-smoking
men, and was associated with net improvement of plasma HDL levels. The quantitative analysis of the
LDL fractions also showed an improvement of LDL lipid composition. Therefore, the supplementation
with AA could exert protective effects against atherosclerosis and related systemic inflammation by
reducing the oxidized LDL and macrophage phagocytosis, with reduced conversion to foam cells [42].
Interestingly, this study demonstrated that AA induced changes in gene expression of
some microRNAs that negatively regulate target genes’ post-transcriptional expression. After AA
consumption, miR155 levels decreased by 90%, suggesting that high doses of AA may significantly
modulate miRNA levels and the anti-inflammatory response [42]. Thus, AA may be considered an
epigenetic key to personalized nutrition.
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5. Evidence for Ascorbic Acid in Brain Aging
In the central nervous system, AA plays a complex role that is still only partially established.
Cerebrospinal fluid (CSF) ascorbic acid concentrations (200–400 mM) are higher compared to those in
cerebral parenchyma and in plasma (30–60 nM) [43].
AA is secreted into the CSF across the apical membrane of choroid plexus cells by an active
and saturable transporter for AA, the sodium-dependent vitamin C transporter 2 (SVCT2). In turn,
dehydroascorbate (DHA) can cross the blood-brain barrier (BBB) more efficiently through the GLUT1
transporter present in the BBB endothelial cells. SVCT2 mediates AA uptake through neurons
or astrocytes in the brain while GLUT receptors (In particular GLUT1 and GLUT3) are primarily
responsible for the DHA absorption from the central nervous system cells. Neurons likely use both
mechanisms to maintain intracellular ascorbate, although SVCT2 transport mostly contributes to
maintaining the ascorbate concentration gradient from CSF to neurons [43]. Moreover, AA recycling
acts through a bystander effect by GLUT receptors mediated cellular uptake in pro-oxidative conditions.
It favors the intracellular conversion from DHA to AA with increased intracellular accumulation. This
bystander effect is responsible for AA recycling activity between neurons and astrocytes and plays a
role in the fine balance between pro-oxidative and anti-oxidative status [53].
Recently, it has been shown that AA release mediated by neurons is linked to glutamate
metabolism and kinetics in the brain. In particular, Wilson et al. [53] demonstrated that AA extracellular
release is the direct consequence of astrocyte swelling mediated by glutamate receptors’ increased
sodium uptake. Heightened AA release in the brain and CSF is considered responsible for its
antioxidant and neuroprotective mechanism against glutamate excitotoxicity [53].
Several in vivo studies documented that AA plays an antioxidative role, especially after an
ischemic event or cerebral reperfusion. AA, at millimolar concentrations, was able to scavenge the
superoxide anion, recycling the α-tocopherol within the lipid layers of the cellular membrane [54].
This, in turn, impeded the lipoperoxidation process. In addition, in the CNS, AA participated in
several hydroxylation reactions that include the redox activity of Fe3+ and Cu2+ at dioxigenase
sites. In vitro studies on cultured stem cells showed that AA is also implicated in neuronal
developmental maturation and in neurotransmission. Lee et al. [55] further demonstrated that AA (at
a 200 millimolar concentration) was effective in differentiating neuronal and astrocytes precursors,
promoting synaptic maturation.
Using SVTC knockout mice as an in vivo model showed that AA, at lower doses, was able to
mediate dendrite formation, increasing post-synaptic electrical potential [56].
AA is essential for the biosynthesis of catecholamines, peptide amination, myelin formation,
synaptic function enhancement, along with the neuroprotective activity against glutamate
toxicity [53,57]. In particular, AA plays an essential role in neurotransmission, because it is a co-factor of
the dopamine beta–hydroxylase enzyme that catalyzes the conversion from dopamine to noradrenaline.
AA is considered to modulate cerebral plasticity by orchestrating neurotransmitter balancing in
the brain. The main AA-mediated mechanisms impacting neurotransmission could relate to redox
modulating activity of the NMDA receptor, supporting a role for AA in counteracting glutamate
excitotoxicity [57,58].
It is expected that better understanding of the physiological and molecular mechanisms associated
with AA brain recycling and the differential expression of SVCT2 and GLUT receptors could contribute
to disentangling the pathogenesis of complex neurodegenerative diseases, such as Alzheimer’s disease
and Huntington’s disease.
6. Ascorbic Acid and Its Relevance to Alzheimer’s Disease
Over the years, L-ascorbic acid (AA) has been increasingly found to promote several beneficial
effects on neurodegeneration, with particular regard to Alzheimer’s disease (AD) [59]. The increasing
burden of this life-threatening condition [60] and the lack of disease-modifying drugs have guided the
research towards preventive strategies, targeting AD modifiable risk factors [12]. Mounting evidence
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indicates a role for L-ascorbic acid in ameliorating specific factors linked to AD pathogenesis [61].
Namely, the main mechanisms associated with AA neuroprotection involve the scavenging activity
against ROS, the modulation of neuroinflammation, the suppression of the fibrillation of amyloid-beta
peptide (Aβ), and the chelation of iron, copper and zinc [62]. The amyloid cascade hypothesis is
considered the primary event of AD pathogenesis [63]. The sequential cleavage by gamma and β
secretase (BACE1) of the β-amyloid precursor protein (APP) results in the production of the β-amyloid
species with neurotoxic oligomer accumulation. Brain accumulation of Aβ1-42 oligomers results in
increased neuronal vulnerability to oxidative stress [64,65] neuroinflammation with impairment of
synaptic plasticity [66], and neuronal death. Extracellular amyloid plaques are also responsible for the
hyperphosphorylation of the cytoskeletal Tau protein [67]. In addition, Aβ oligomers interfere with
mitochondrial dynamics [68,69].
Copper, zinc, and iron are present in Aβ plaques due to the presence of metal binding sites [70].
Metals can affect the morphology of Aβ, accelerating fibrillation and cytotoxicity of Aβ [71]. Therefore,
redox active copper and iron linked to Aβ can generate hydroxyl radicals via the Fenton reaction,
increasing protein and DNA oxidation and lipid peroxidation (MDA) in the AD brain. Metal redox
activity also induces the production of AGEs, carbonyls, peroxynitrites, and increased levels of heme
oxygenase-1 (HO-1), with decreased cytochrome c oxidase activity [61]. AGEs, through their interaction
with receptors for advanced glycation end products (RAGEs), further activate pro-inflammatory
pathways with the induction of pro-inflammatory cytokines, such as IL-6 [72]. In addition, lower
concentrations of the fluorescent AGE pentosidine were observed in the CSF of AD patients, compared
to healthy subjects, in support of a role for altered AGE metabolism in AD pathogenesis [73].
Oxidative stress is generally associated with chronological aging, while aging is the major
epigenetic risk factor for AD. Recent evidence has found that oxidative stress plays an essential
role in the pre-phase of AD, including mild cognitive impairment [74]. The brain is vulnerable to ROS
damage due to neurons’ post-mitotic state with higher oxygen consumption. With respect to lipid
peroxidation products, oxidized proteins, and DNA damage, peroxynitrites have been increasingly
detected in the AD temporal cortex, as well as oxidation of mitochondrial DNA and nuclear DNA
in the parietal cortex [75]. In AD hippocampal neurons and astrocytes, a redox imbalance has been
observed with an overexpression of heme oxygenase-1 and increased levels of Cu/Zn superoxide
dismutase [76]. The conjugated aromatic ring of tyrosine residues is also a target for free-radical
attack, and accumulation of dityrosine and 3-nitrotyrosine has also been reported in the AD brain [77].
Therefore, oxidative stress can directly activate glia with the priming of astrocytes and microglia at
the injury site. In turn, the direct contact of activated glial cells with neurons may generate immune
mediators (nitric oxide, ROS, pro-inflammatory cytokines, and chemokines) that are neurotoxins,
spreading inflammation in the central nervous system [78,79]. Thus, extensive oxidative damage
may act as a driver of brain aging, and early accumulation of oxidatively modified biomolecules may
constitute the initial steps of AD neurodegeneration.
All of these findings could provide a mechanistic role for oxidative stress as a direct effect of
aging and a consequence of the toxic effect of Aβ. Oxidative stress interacts with multiple features
associated with AD pathogenesis, such as APP processing, mitochondrial dysfunction, and metal
accumulation [80]. The main AA mediated neuroprotective effects on AD pathogenesis are reported
and illustrated in Table 2.
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Table 2. In vitro and in vivo evidence for a role of AA in Alzheimer’s disease.
Species Model Design and Methods Conclusion References
Mouse TASTPM Evaluation of carbonyls, glutathione, Aβ, APP Decreased oxidative stress markers, Nrf2, GSH, APP, solubleAβ1-42. No increase of BACE 1, PS1and AB plaque Choundhry, F. 2012 [58]
Mouse Model with human APP695 anddouble mutation (K670N, M671L)
Evaluation of Aβ, BACE1, antioxidant system
and IL-1β
Increased antioxidant system, reduced activity of BACE,
IL-1β and NO levels, Aβ deposition Apelt, J. 2004 [60]
Mouse APP/PS1 transgenic ROS scavengers and inhibitors effects onAβ-induced impairments in LTP
Reversal of Aβ- deposition by mitochondria-targeted
ROS scavenging Ma, T. 2011 [62]
Mouse HAPP/Sod1−/− Anti-Aβ1-16 antibody Inhibition of amyloid plaques (Aβ hexamers/BACE1 modulation) Murakami, K. 2012 [65]
Mouse Tg2576 Aβ levels brain deposition
Suppressed brain inflammatory and oxidative stress
responses in mice, significant reduction of soluble and
insoluble Aβ1-40 and Aβ1-42
Yao, Y. 2004 [57]
Mouse APPS we/PSEN1∆E9 MDA, Aβ levels, AChE activity. Learningand memory
Improvement of learning and memory Beneficial effects
against MDA, and Beneficial effects on AChE function Harrison, F.E. 2009 [50]
Mouse APPSWE/PSEN1∆E9 mice,SVCT2+/− Behavioural test, GSH, MDA, isoprostanes
Decreased Aβ deposition (senile plaque formation
and accumulation) Dixit, S. 2015 [81]





Cognitive test, cytokines, ROS Cytotoxic
Activity Assay Enhancement of anti-oxidative pathway Sil, S. 2016 [83]
Mouse Gulo−/−5XFAD Identification modification of cerebral capillaries Reduction of Aβ accumulation Kook, S.Y. 2014 [84]
In Vitro neuroblastoma cell line SH-SY5Y Apoptosis (phosphatidylserine, TUNEL assay,caspase-3 activity) Prevention of toxicity induced by Aβ Huang, J. 2006 [85]
Mouse Tg2576, 3xTg-AD Aβ staining, investigation APP andHS oligosaccharides Modulation of Aβ fibrillogenesis Cheng, F. 2011 [86]
Mouse AD model Fibrillogenesis: senile plaques Modulation of synaptophysin and the phosphorylation of tauat Ser396 Murakami, K. 2011 [87]
Rat Wistar Lipoperoxidation, oxidation,Inflammation, nitrites
Reduction of pro-inflammatory cytokine Inhibition of
Aβ deposition Rosales-Corral, S. 2003 [88]
Human
In Vitro NT2 undifferentiated cells
Measurement levels of Aβx-40 and Aβx-42,
HNE, expression of BACE-1. Evaluation
apoptotic cell death induced by HNE
Increased anti-oxidative pathways against SAPK pathways
and BACE-1 that regulate AβPP processing Tamagno, E. 2005 [74]
Human
In Vitro Neuroblastoma cell line SH-SY5Y Glutathione, superoxide dismutase, and catalase
Neuroprotection anti-oxidative pathways Improvement of
antioxidant defense system Ballaz, S. 2013 [80]
Rat PND7
Induction of ROS, apoptotic markers.
Quantification of Bax/Bcl-2 ratio, cytochrome c
and caspases
Reduction of oxidation, neuroinflammation (both activated
microglia and astrocytes). reduced ethanol-induced activation
of PARP-1 and neurodegeneration
Ahmad, A. 2016 [89]
In Vitro EA. hy926 cells Measurement intracellular ascorbate and GSH Endothelial integrity (NO: eNOS/guanylate cyclase pathway) May, J.M. 2011 [90]
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Table 2. Cont.
Species Model Design and Methods Conclusion References
In Vitro EA. hy926 cells Quantification LDL-enriched lipoproteins, GSH,and lipid peroxidation Endothelial integrity May, J.M. 2010 [91]
Rat Cortical neuron/glia co-culturesof neonatal
Measuring nitrites IL-6 and MIP-2, LDH. p38
and ERK MAPKs
Suppression of the LPS-stimulated production of
inflammatory mediators Huang, Y.N. 2014 [92]
Rat Sprague–Dawley Behavioural test BBB components Modulation of cortical compression and/or BBB dysfunction Lin, J.L. 2010 [12]
Rat MCAO
Measurement of infarct and edema brain,
measurement of serum MMP-9 levels,
behavioural testing
decreased MMP-9 levels, Improvement of the vascular insult
(BBB disruption and brain edema) Allahtavakoli, M. 2015 [93]
Rat Brains Assessment the role of nanocapsulated ascorbicacid (NAA)
NAA exerted protection to brain mitochondria by preventing
oxidative damage in ROS mediated CIR injury Sarkar, S. 2016 [94]
Rat Hippocampal neurons Incubation with Aβ Os or 4-CMC ± NAC NAC prevention of Aβ O-induced mitochondrialFragmentation by anti-oxidative pathways Sanmartin, C.D. 2012 [61]
Rat Cortical neuronsNeuroblastoma cells
Oxidative stress and DHA uptake, analysis
of GLUTs Improvement of anti-oxidative defense of neurons García-Krauss, A. 2016 [75]
Rat Primary neurons Incubation with H2O2, ratio GSH/GSSG Increased glutathione system of peroxide detoxification Dringen, R. 1999 [78]
Rat Astroglial cells Treatment with H2O2 or hydro peroxide, NOrelease, Lipid Peroxidation, ROS Reduction of neuroinflammation (microglial-astroglial cells) Röhl, C. 2010 [79]
Rat SD Induction of transient focal cerebral ischemia,treatment with DHA
DHA reduced brain edema and vascular permeability
formation following cerebral ischemia Song, J. 2015 [95]
Human Endothelial cell (HBMEC) andastrocyte co-colture BBB after hyperglycaemic insult
Improvement of BBB permeability by reducing oxidative
stress associated with glucose normalization Allen, C.L. 2009 [96]
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6.1. Ascorbic Acid and Oxidative Stress in Alzheimer’s Disease
AA is suggested to play a major role in the pathogenesis of AD by direct neuroprotection
against oxidative stress. Imbalance of AA homeostasis has been extensively demonstrated in
neurodegeneration [58]. AA is a key antioxidant of the CNS, released from glial cells to the synaptic
cleft, and taken up by neurons as an antioxidant defense to maintain neuronal metabolism and synaptic
function. The astrocyte-neuron interaction was found to function as an essential mechanism for AA
recycling, participating in the anti- oxidative defense of the brain [97].
It is well documented that AA is a first-line antioxidant defense to neutralize ROS reactivity,
promoting the regeneration of endogenous antioxidants (GSH, catalase, vitamin E) [98].
Interestingly, it is also presumed that AA moderates the oxidative stress mediated by glutamate,
protecting from excitotoxicity in the brain [56,88]. A previous study in APP/PSEN 1 transgenic mice
showed that parenteral administration of AA possessed nootropic properties, without altering the
AD-like features of plaque deposition, oxidative stress and acetylcholinesterase activity [85]. Therefore,
several in vitro and in vivo studies underpin the therapeutic role of AA in AD, bolstering oxidative
defense [99].
In rat hippocampal brains, oral administration of AA reduced oxidative stress and
neuroinflammation mediated by Aβ fibrils [100]. Additionally, AA was shown to protect SH-SY5Y
neuroblastoma cells from apoptosis mediated by Aβ [86], decreasing the rate of endogenous amyloid
generation. Further, AA was reported to decrease acetylcholinesterase activity in mice [101] and to
positively restore presynaptic acetylcholine release [102].
More recently, the NO-catalyzed release of anhydromannose in the presence of AA was
detected [103] with an associated decreased formation of toxic Aβ oligomers. APP/PSEN 1
mice lacking the SVCT2 transporter and having AA mild deficiency showed accelerated amyloid
pathogenesis, linked to oxidative stress pathways, compared to control mice with normal brain ascorbic
acid [81]. Further, orally-administered AA reduced oxidative stress and pro-inflammatory cytokines
induced by Aβ peptide injections in the CA1 area of the hippocampus in rat brains [99].
6.2. Metals, Oxidative Stress and Ascorbic Acid in Alzheimer’s Disease: The AA Oxidative Balance in the Brain
The main features of enhanced oxidative stress in the AD brain are also related to the increased
content of Cu and Fe, capable of stimulating free radical generation, lipid peroxidation, reactive
nitrogen species (NRS) release, and stress-sensitive proteins [104]. In turn, the interaction of the
redox-active copper ions with misfolded Aβ aggregates and oligomers may favor AD pathogenesis.
It is well known that at higher concentrations, AA acts as a pro-oxidant, either by generating
reactive oxygen species or by inhibiting the antioxidant systems in the presence of iron, which, in
turn, induces lipid peroxidation [105]. A pro-oxidant or antioxidant effect of AA mainly relies on the
concentration gradient and redox state of a cell [106]. Evidence from a mouse model that selectively
over-expressed the AA transporter SVCT2 in the eye [107] implicated AA in age-related damage to
crystalline proteins in the lens. All of these experimental data contribute to heightening the debate on
the potential pro-oxidant role of AA via the Fenton reaction.
A previous study undermined the protective role of AA in dementia, indicating that the interaction
of AA with ‘free’ catalytically-active metal ions could contribute to oxidative damage through the
production of hydroxyl and alkoxyl radicals [108]. Interestingly, some in vitro studies investigated the
pro-oxidant properties of ascorbate [109], which were mainly attributed to the release of metal ions
from damaged cells. It has been reported that neurotoxic forms of amyloid β, Aβ (1–42), Aβ (1–40),
and also Aβ (25–35) induced copper-mediated oxidation of ascorbate, whereas non-toxic Aβ (40–1)
did not [110,111]. It was concluded that toxic Aβ peptides mediated copper-oxidation of ascorbate
with the generation of hydroxyl radicals, indicating a role for cupric-amyloid peptide’s free radical
generation in the pathogenesis of AD. In line with these last findings, Aβ was not found to silence
the redox activity of Cu2+/+ via chelation, but rather hydroxyl radicals were produced as a result
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of Fenton-Haber Weiss reactions of ascorbate and Cu2+, rapidly quenching harmful radicals [112].
Moreover, reaction rates and mechanisms of AA oxidation resulted in greater biological relevance in
the presence of Cu(II)-containing Aβ oligomers and fibrils, given the close proximity of ROS to cell
membranes [104]. Further evidence indicated a pro-oxidative role for AA in the interaction of the
redox-active copper ions with misfolded amyloid β and AD pathogenesis, with particular relevance to
catalytic sites for Cu+ present in full-length Aβ instead of in any particular Aβ conformation [82].
However, to complicate the issue, AA was observed to reduce in vivo oxidative damage in the
presence of iron, despite its well-known in vitro pro-oxidant properties in buffer systems containing
iron [83]. In addition, a recent report evaluated the in vitro effects of different food constituents
on brain metal chelation, oxidative stress, and fibrillogenesis [89]. The results did not support the
currently hypothesized AA neuroprotective mechanisms of action. Indeed, AA was found to be a good
antioxidant with poor metal chelating activity. Strikingly, the study did not show any AA-mediated
inhibiting effect on Aβ fibrillogenesis, compared to the multifunctional food abilities of epigallocatechin
gallate (EGCG), gallic acid, and curcumin. Hence, due to good AA brain uptake, further investigation
is needed to address the role of ascorbic acid in counteracting oxidative stress in an AD brain.
6.3. Ascorbic Acid and Neuroinflammation in Alzheimer’s Disease
A previous study demonstrated that chronic administration of AA in the brain chronically
infused with lipopolysaccharide and tiorphan was associated with increased deposition of Aβ amyloid
plaques and increased Aβ neuronal immunoreactivity [92]. However, a body of evidence implicated
AA in the suppression of glia-mediated inflammation. In particular, a colchicine-induced oxidative
stress/neuroinflammation AD rat model [84] showed that administration of AA was effective in
preventive memory impairment, and reducing inflammatory markers (TNF alpha, IL 1 beta), ROS,
and nitrite levels in the hippocampus of AD rats. AA also significantly reduced amyloid plaque
formation. Peripheral immune response (increased phagocytic activity of blood WBC and splenic
PMN) was also recovered after AA administration and the observed changes were associated with the
higher efflux of inflammatory mediators from the brain to peripheral circulation. The same results
also addressed a pro-oxidant role of AA at higher doses (600 mg diet), supporting the dual role of
AA in addressing the oxidative stress. In addition, a rat model of ethanol-induced oxidative stress
showed that AA was effective in counteracting ethanol-induced oxidative stress, neuroinflammation,
and apoptotic neuronal loss with beneficial effects against ethanol damage to brain development [87].
Even if the model is not a true AD model, the current findings add knowledge to the role of AA against
oxidative stress and neuroinflammation in the brain. In particular, due to its free radical scavenging
properties, AA treatment reduced the production of ROS and suppressed both activated microglia and
astrocytes. AA also demonstrated mitigation of apoptosis and neurotoxicity by decreasing levels of
the Bax/Bcl-2 ratio, cytochrome C, and different caspases, such as caspase-9 and caspase-3. Moreover,
AA treatment reduced ethanol-induced activation of poly [ADP-ribose] polymerase 1 (PARP-1) and
neurodegeneration. In line with these data, AA was also observed to suppress the lipopolysaccharide
(LPS)-stimulated production of inflammatory mediators in neuron/glia co-cultures by inhibiting the
MAPK and NF-κB signaling pathways [113].
6.4. Ascorbic Acid and Amyloid Plaque Accumulation in Alzheimer’s Disease
Accumulating evidence indicates a role for AA on the toxic fibrillogenesis of Aβ. High doses of
AA supplementation reduced the amyloid plaque burden in a 5 familial Alzheimer’s disease mutation
(5XFAD) AD mouse model. To better identify the pathogenetic importance of AA in an AD mouse
model, the cross-breeding of 5XFAD mice with gulono-gamma-lactone oxidase (Gulo) knockout mice
was performed (KO-Tg mice). The higher supplementation of AA in KO-Tg mice resulted in the
amelioration of BBB disruption and mitochondrial alteration, with substantial reduction of amyloid
plaque burden [114].
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The APPSWE/PSEN1deltaE9 mouse model of AD, created by crossing APP/PSEN1(+)
bigenic mice with SVCT2(+/−) heterozygous knockout mice, also showed interesting results [81].
By 14 months of age, increased oxidative stress was observed (malondialdehyde, protein carbonyls,
F2-isoprostanes) with decreased total glutathione, compared to wild-type controls. In addition,
increased amounts of both soluble and insoluble Aβ1-42, and a higher Aβ1-42/1-40 ratio with increased
hippocampal and cortical amyloid-β plaque deposits were observed, compared to APP/PSEN1(+)
mice with normal AA brains. These data suggested that AA deficiency plays an important role in
accelerating amyloid accumulation, particularly during early stages of disease, and that these effects
are likely modulated by oxidative stress pathways. Huang et al. showed that pre-loading cells with
ascorbate substantially prevented apoptosis and death of SH-SY5Y cells, while also decreasing basal
rates of endogenous beta-amyloid generation [86]. Cheng et al. demonstrated, in an in vitro model,
that an inadequate supply of AA could contribute to the increased formation of toxic Aβ oligomers.
In the absence of AA, the temporary interaction between the Aβ domain and small NO-catalyzed
release of anhydromannose (anMan)-containing oligosaccharides is prevented, with the increased
induction of neurotoxic fibrillogenesis [103]. Murakami et al. [91], in APP transgenic mice, showed
that AA administration attenuated oligomerization, but not the total amyloid plaque volume. The
authors concluded that the ability of mice to retain de novo synthesis of AA is possible, and a longer
study duration is needed to appreciate the significant changes in amyloid plaque accumulation. These
last findings are original and indicate the need to test the “sink hypothesis” through the systematic
assessment of cerebrospinal fluid AA levels in order to support the role of AA in promoting healthy
brain aging. Indeed, it is hypothesized that there is some form of equilibrium for the Aβ in the brain
and the periphery such that Aβ can be transported across the blood-brain barrier. By modulating
the peripheral Aβ levels, it is predicted that the brain Aβ levels will undergo concomitant changes,
forming the basis of the “sink hypothesis” for Aβ lowering strategies.
6.5. Acid Ascorbic and Vascular Disease Associated with Alzheimer’s Disease
Recently, a pathophysiological role of the vascular component in the pathogenesis of AD has
been demonstrated [115]. Again, oxidative stress is considered a key relevant mediator, confirming
the pathogenetic link between AD and vascular disease [116]. Oxidative stress may affect the
neurovascular unit, by impairing the endothelial integrity with increased Aβ42 production. This series
of pathological events resulted in automatically maintaining the cycle between ROS overproduction
and new extracellular Aβ42 deposition. It was ascertained that AA mediates a series of protective
effects on brain neurodegeneration by reducing intima-media thickness, lipid peroxidation, and
endothelial dysfunction [90,116–119]. In keeping with this, it has been recently documented that
the integrity of the endothelial lining in the blood-brain barrier is essential to prevent the onset
of AD [120–122]. Each of these vascular risk factors may represent a biological target for AA and
contribute to the preventative role of AA in the development of AD pathogenesis, associated with the
vascular component.
Growing evidence indicates a role for AA in reducing cardiovascular related mortality and overall
mortality, according to higher quartile plasma AA concentrations in humans [123]. Interestingly, it
should be noted that the higher risk of carotid intima thickness >1.2 mm was exclusively associated
with the lowest plasma AA tertile. This same increased risk was not observed with uric acid, vitamin
A, or enzymatic antioxidant load (superoxide dismutase and glutathione oxidase activity). Similarly,
dietetic interventions in elderly subjects showed that carotid intima thickness progression was reduced
only in those subjects taking AA daily.
The risk of either AD or vascular dementia is higher in patients with elevated blood pressure,
which suggests how arterial stiffness and atherosclerosis play important pathogenetic roles [123].
Endothelial dysfunction is associated with arterial stiffness which, in turn, is a strong predictor for
cognitive decline [124]. All of these data support the role for AA in modifying vascular risk factors
associated with Alzheimer’s-type dementia.
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Endothelial dysfunction is a crucial factor associated with AD pathogenesis. Aβ aggregates are
cleared from the brain across the BBB, as the transport is finely regulated by RAGE receptors and LDL
receptor-related protein (LRP-1). In patients with AD, brain endothelial LRP-1 expression throughout
the BBB is reduced [125]. These data suggested an essential role of the endothelial cell integrity
lining in the onset and progression of AD. The efficacy of AA against BBB breakdown due to cortical
compression was reported [90]. A model of ischemic-reperfusion [126] and BBB breakdown with
reduced NO bioavailability may be considered a prototypical model to understand the pleiotropic roles
of AA on endothelial function. AA regulates endothelial integrity via oxidative pathways; superoxide
generated by endothelial cells reacts with NO to form cytotoxic peroxynitrites and AA could decrease
NO consumption by scavenging superoxide. In addition, AA was found to play a role in the function of
endothelial nitric oxide synthase (eNOS) by recycling the eNOS co-factor, tetrahydrobiopterin, which is
relevant for arterial elasticity and blood pressure regulation [18]. AA also favored the restoration of NO
metabolism from S-nitrosothiols in plasma [127], reducing nitrite (NO2) to NO, which may preserve
NO in tissues or plasma. AA was reported to reverse the generation and metabolism of NO [94], and
to prevent endothelial dysfunction by inhibiting LDL oxidation. An oxidized endothelium is known to
increase BBB permeability [117] and the AA-associated protective mechanism on lipid metabolism
was found to improve BBB endothelial disruption. In addition, AA prevented the impaired response
to the vasodilator acetylcholine (endothelium-dependent agonist) and reduced ROS (e.g., superoxide)
produced by neutrophils [93]. Thus, a series of studies have suggested that AA may protect from AD
onset, by protecting BBB integrity.
So far, scant investigations have explored the effects of anti-oxidative vitamins on dementia
through the cerebrovascular axis [95]. The study of Kook et al. [87] recently reported that high-dose
supplementation of AA reduced amyloidosis in AD mice (5XFAD) via the reduction of BBB disruption
and mitochondrial alteration [96]. Additionally, AA was also reported to prevent the disruption of
BBB by upregulating the expression of tight junction proteins, occludin and claudin-5.
In a model of stroke with substantial BBB disruption, AA significantly reduced BBB
permeability [128]. Similarly, in a mouse model of cerebral ischemia, AA ameliorated BBB dysfunction
by reversing tight junction claudin-5 and attenuated edema and neuronal loss [129]. Moreover, an
in vitro study provided evidence that AA reversed hyperglycemia-mediated BBB disruption [130]. To
date, AA seems to offer neuroprotection by restoring BBB integrity. However, further investigations
should focus on simultaneously testing brain neuroprotective effects and BBB protective effects of
antioxidants [95]. AA seems to possess both types of neuroprotection and could be further tested as a
targeted dual agent for preventing cognitive decline.
Several cross-sectional studies have demonstrated a lower CSF-to-plasma AA ratio in AD
patients compared to controls. In particular, recent findings [95] suggest that maintenance of a high
CSF-to-plasma AA ratio is important in preventing cognitive decline in AD and that BBB impairment
unfavorably affects this ratio. However, whether the AA transport carrier dysfunction (SVCT2) or the
disturbed BBB integrity is responsible for it, is still a matter of debate.
Indeed, the loss of BBB integrity seen in elderly people with dementia may hamper the brain’s
ability to retain CNS AA regardless of the successful transport [131–133]. Genetic variations of the
SVCT2 carrier at the choroid plexus and in neurons may also play a significant role. In line with
these data, a recent review has concluded that CSF levels within the normal range for AA indicate
the preservation of choroid plexus function and AA transport into the CSF [134], despite lower
plasma levels.
7. From Bench to Bedside
Ascorbic acid levels in plasma are decreased in AD patients [135] and the association between
cognitive impairment and low antioxidant status is accumulating. Indeed, it has been suggested
that increased dietary intake may reduce the risk of developing AD. So far, whether oxidative stress
Nutrients 2017, 9, 670 16 of 26
associated with the disease is responsible for the reduction of antioxidants, or whether the low
antioxidants contribute to the progression of the disease has not been ascertained.
However, plasma levels of AA were found to be lower both in patients with mild cognitive
impairment and AD, compared to controls [136].
A further difference existed between undernourished patients with dementia and patients taking
any antioxidant supplement.
From bench to bedside, eight large population studies [57] have investigated the association
between AA intake and Alzheimer’s-type dementia in both European countries and the US. However,
the neuroprotection associated with AA has not yet been established. According to the CHAP
study [137], none of the elderly dementia-free participants longitudinally developed dementia, due to
AA supplementation. In contrast, a synergistic association between AA and vitamin E supplementation
was shown in reducing the risk of AD [138]. Another large population study has shown a protective
role for AA in vascular dementia and cognitively-intact subjects, but no protective role of AA was
shown for Alzheimer’s disease [139].
The Rotterdam study showed the most consistent association between higher AA intake and
reduced relative risk for AD in the largest population study [140] with the higher magnitude of
association in people most depleted of AA (e.g., smokers). The same study found an association
for lower levels of vitamin E in AD patients at follow up an average of 9.6 years later, but not for
AA intake.
Additionally, eleven studies have examined the relationship between plasma AA and cognitive
decline, including AD, and four of them examined CSF AA and CSF-to-plasma AA ratios. An early
study of Goodwin [29] assigned patients to AA plasmatic deficiency according to tertiles. The main
findings suggested a significant association between AA deficiency below 20 µM, mild cognitive
impairment, and AD patients compared to healthy controls, even after correction for co- morbidities,
age, and fruit/vegetables intake.
The study of Quinn [141] showed that the mean CSF-to-plasma AA ratio was significantly lower
in AD compared with controls. A further prospective analysis of CSF AA, rates of cognitive decline,
and BBB did not draw final conclusions, but a higher CSF-to-plasma AA ratio was associated with a
slower rate of decline [57].
Conversely, several clinical studies did not show any beneficial effect of AA on cognition in
patients with AD. In a population study of North Carolina, 616 elders aged over 75 years and
long-term supplement users of AA did not show any neuroprotection against developing AD [142].
However, no record was made of dietary intake, and the results outlined that less healthy behaviors
and socioeconomic status were associated with the poorer cognitive outcomes. Vitamin E levels
were significantly lower in the AD group than controls while AA levels did not differ significantly
between groups.
A series of limitations may count for interpreting the clinical results. There is substantial
inconsistency among the observational studies on AA intake, plasma levels, beneficial effects on
aging and cognition.
It is noteworthy that a great deal of clinical studies usually excluded elderly people if they had
polypharmacy or comorbidity. These exclusion criteria critically undermine the validity of results,
leaving out the populations most at risk for AA deficiency.
Approximately 17% of the elderly population did not meet the RDA for AA intake, which critically
suggests that large elderly population groups show depleted levels of AA; this determinant may count
for the disparate conclusions of different clinical studies. In particular, as accurately summarized by
Harrison F et al. [143], the classification of groups according to AA status differs greatly among studies.
The deficiency levels of AA are lower than 11 µmol/L, with suboptimal concentrations between
11–38 µmol/L, adequate plasmatic concentrations of AA above 28 µmol/L and optimal concentrations
between 50–60 µmol/L (µmol/L: conversion factor 56.78 from mg/dL concentrations of AA).
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Moreover, the range of AA supplements greatly vary from 27 to 230–270 mg/day, introducing
another element of variability.
Not least, the higher intakes of AA were associated with beneficial effects on cognition if not
exceeding 500 mg/day; higher plasmatic values (1 g/day) of AA were associated with poorer
cognitive performance.
The beneficial effects of AA need reliable plasmatic determinations with repeated points of
measurement. The lack of accuracy in study designs and methodologies may also affect the reliability
of the findings [57]. In addition, the lack of standardization between single nutrient consumption or
multivitamins and the lack of systematic detection of plasmatic levels of AA also affect the accuracy
of outcomes.
Moreover, the missing consideration of specific AA metabolism, the inaccurate daily estimate
of AA consumption, and the erroneous intestine-to-bloodstream absorption due to saturable AA
transporters being critical determinants for drawing appropriate conclusions [57]. The variability of the
results may also be ascribed to difference of plasma AA concentrations according to polymorphisms of
SVCT2 and SVCT1 despite equivalent AA intake. This difference indicates that SVCT1/2 genotype may
play an important role in the association between AA intake and circulating AA levels. Furthermore,
the difference between food intake and synthetic supplements and the mean of their bioavailability
need to be clearly defined.
It should also be noted that the current intake of AA may not accurately reflect the subjects’
lifetime habits; this, in turn, may substantially affect the biological trajectory of Alzheimer’s disease
with particular regard to early mid-life deposition of amyloid plaque. Thus, the stratification of
different aging populations according to their clinical vulnerability, cognitive reserve, comorbidity and
specific risk profile could add knowledge to this field [95]. Similarly, a greater understanding of the
modulation between pro-oxidative AA status and antioxidative capacity during aging and age-related
specific conditions, including dementia, is warranted.
Currently, the clinical data yield inconsistent results. AA supplementation showed beneficial
effects when restoring a nutritional deficit or preventing vitamin deficiency; thus, it seems more
plausible that avoiding AA deficiency is likely to be more beneficial than taking supplements on top of
a normal healthy diet.
So far, the levels of AA needed to beneficially modify brain aging are largely unknown. A causal
association between AA deficiency and cognitive decline, including dementia, is still debated and two
main issues are unanswered. Namely, the co-causal role of AA deficiency versus its epiphenomenal role
in AD neurodegeneration has not yet been established. However, AA’s strong free radical scavenging
properties, the well-characterized kinetics of transport, and the good bioavailability in the CNS provide
a favorable background for further exploring its role in promoting brain function and healthy aging.
With testing by neuroimaging, recent research has demonstrated that it is possible to detect
brain levels of AA by using a MEGA-PRESS mediated spectra (MEGA-PRESS, MEGA-point-resolved
spectroscopy) [144]. The study indicated a relationship between brain and blood AA levels and
provides a new conceptual framework for future studies, further exploring the role of AA in the brain.
8. Conclusions
In conclusion, randomized clinical trials have failed to demonstrate any association between
AA-mediated antioxidant therapeutic activity and a delay in AD neurodegeneration.
However, the assessment of the “sink hypothesis” could substantiate a crucial role for AA in
promoting healthy aging of the brain. The analysis of AA concentration in plasma, CSF, and the ratio
of AA/glutamate, along with the role of AA-related carriers (SVCT2 SNPs) and barriers to its brain
transport (BBB) could significantly spur this research field by directly analyzing the AA concentrations
in the brain.
Neuroimaging measures also hold promise in offering deeper insights on the structural, metabolic,
and connective role that AA plays in the brain [144], contributing to the larger picture.
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Additionally, animal models need to be further investigated with a particular focus on
gulonolactone oxidase knockout models that mimic human physiology, and may help identify novel
AA mechanisms of action to promote healthy aging of the brain.
Another intriguing area of research could address the protective association between AA and
glutamate transport/NMDA receptors to critically evaluate the AA role in neurodegeneration.
Finally, the field of epigenetics has recently answered the question as to why AA is
disproportionally concentrated in CSF and brain parenchyma compared to plasma [28]. Nutrition
represents one of the most powerful environmental modifications of the genome. Recent research has
assessed a peculiar epigenetic role for AA. Namely, the oxidation of 5-mc (5-methylcytosine) to 5-hmc
(5-hydroxymethylcytosine), as part of dynamic DNA demethylation, is catalyzed by TET (ten-eleven
translocation) dioxygenase enzymes, for which AA is a critical co-factor [23,145]. Interestingly, no
other antioxidant displayed such an epigenetic mechanism. Thus, AA can be considered vital for
neuronal repair and offers new molecular mechanisms to understand the true neuroprotective role of
AA in brain aging and neurodegeneration.
In addition, it has been recently documented that 75% of ascorbic acid degradation is due to
Maillard degradation pathways (amide-AGEs) [146]. Knowledge of the mechanisms of Maillard model
systems could help understand the changes occurring during storage and processing of AA-containing
food, as well as in vivo modifications.
Thus, all of these lines of research could improve the understanding of the role of AA in brain
aging and, hopefully, provide a new conceptual framework for AD in the near future.
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